Loading
companiesCompany
Intergroupe Francophone de Cancérologie Thoracique
aka IFCT
The French thoracic oncology intergroup, which ran the national Biomarkers France programme showing that routine molecular testing of lung cancer improves survival.
Overview
Founded in 1999, IFCT unites French pulmonologists, oncologists, radiotherapists and pathologists in academic lung cancer trials. Its Biomarkers France study (2012-2013) profiled more than 17,000 patients with non-small cell lung cancer for EGFR, ALK, KRAS, BRAF, HER2 and PIK3CA alterations and showed that testing changes treatment and outcomes at national scale. IFCT trials have covered adjuvant chemotherapy, maintenance strategies, immunotherapy in elderly patients and rare thoracic tumours, and the group runs the CLINIVO real-world immunotherapy cohort. It works with UNICANCER, EORTC and ETOP.
Headquarters
Paris, FR
Website
Founded
1999
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to Intergroupe Francophone de Cancérologie Thoracique, including child institutions. 30 works · 137 citations · 47% open access · 27% clinical trials · 0% reviews.
Oncology works per year
32022
52023
102024
72025
52026
Most works
- Alexandra Langlais17 works
- Franck Morin14 works
- Céline Mascaux10 works
- Virginie Westeel10 works
- D. Debieuvre8 works
- Gérard Zalcman8 works
- Laurent Greillier8 works
- A. Dixmier8 works
- Anne Madroszyk7 works
- Olivier Molinier7 works
Most cited
Alexis Cortot
President
Thoracic oncologyLung cancerPulmonology
Lille pulmonologist and thoracic oncologist who presides over the IFCT, France's academic lung cancer trials group.
David Planchard
Board member (Conseil d'Administration)
Thoracic oncologyLung cancerTargeted therapy
Gustave Roussy thoracic oncologist on the IFCT board, widely published on BRAF- and EGFR-targeted therapy in lung cancer.
Fabrice Barlesi
Director General, Gustave Roussy; thoracic oncologist
Thoracic oncologyImmunotherapyPrecision medicine
Fabrice Barlesi runs Europe's largest cancer centre and is a leading lung cancer trialist.
Benjamin Besse
Head of Clinical Research, Gustave Roussy; thoracic oncologist
Thoracic oncologyADCs in lung cancerOncogene-driven NSCLC
Benjamin Besse is a lung cancer trialist central to the Dato-DXd and HER3-DXd lung programmes.
Notes
top- Biomarkers France (national molecular testing study)
- Immunotherapy in elderly and PS2 patients
- Mesothelioma and thymic tumour trials
- CLINIVO real-world cohort
Similar pages
not linked directly; found by shared links- CompanyWest Japan Oncology Group
Shares Oncogene addiction, Small-cell lung cancer, Small-molecule kinase inhibitors, Immune checkpoint inhibitors and the tag cooperative-group.
- CompanyARCAGY-GINECO
- CompanyKorean Cancer Study Group
Shares Comprehensive genomic profiling, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag cooperative-group.
- CompanyBreast Cancer Trials
Shares ETOP IBCSG Partners Foundation and the tag cooperative-group.
- CompanyBreast International Group (BIG)
Shares ETOP IBCSG Partners Foundation and the tag cooperative-group.
- CompanyFrench Sarcoma Group
Shares Gustave Roussy and the tag cooperative-group.
- CompanyAlliance for Clinical Trials in Oncology
Shares ETOP IBCSG Partners Foundation and the tag cooperative-group.
- CompanyGIMEMA
Shares Small-molecule kinase inhibitors and the tag cooperative-group.